Announcement • Jan 24
TempraMed Technologies Ltd. Announces Commercial Launch of VIVI Med
TempraMed Technologies Ltd. announced the commercial launch of VIVI Med, a new temperature-protection solution designed to safeguard medication vials, biologics, and other critical therapies that fall outside the insulin-pen format. The launch of VIVI Med provides significant expansion of the Company's total addressable market opportunity, by extending its proven thermal-protection technology into new drug categories, broader patient populations, and higher-value use cases. By addressing medications such as GLP-1 receptor agonists, biologics including Humira®?, insulin vials, injectable medication vials, and temperature-sensitive blood glucose test strips, VIVI Med™? substantially increases the scope of the Company's commercial reach. As the global use of biologics, GLP-1 therapies, and specialty injectables continues to grow across chronic, autoimmune, and metabolic conditions, the need for reliable, portable, and power-free temperature protection is becoming increasingly critical. VIVI Med™? is engineered to provide 24/7/365 passive protection for years-without batteries, charging, or maintenance-supporting real-world use across travel, work, and active lifestyles. Expanded Compatibility: Designed for medications beyond standard insulin pens, including vials, biologics the GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips. Year-Round Temperature Protection: Maintains safe medication temperatures without refrigeration, electricity, or maintenance. Portable and Lifestyle-Friendly: Compact, lightweight, reusable design for daily use, travel, and outdoor environments.urable, Long-Life Construction: Built with space-grade materials and engineered for years of repeated use. Strategic and Commercial Significance. With the introduction of VIVI Med™?, TempraMed now offers a multi-format temperature-protection platform spanning: VIVI Cap and VIVI Cap Smart™?. for insulin pens and certain GLP-1 pens. VIVI Epi™? for epinephrine auto-in injectors. VIVI MedTM for vials, biologics, GLP-1 pens, test strips, and broader injectable formats This expanded portfolio positions TempraMed to pursue larger and more diversified revenue opportunities, including: Patients using high-cost biologics and GLP-1 therapies. Healthcare providers and specialty pharmacies managing vial-based medications. Institutional and B2B partners seeking standardized medication-protection solutions. Management believes VIVI Med strengthens TempraMed's long-term growth profile by increasing. product breadth, reducing reliance on any single medication format, and supporting future reimbursement, enterprise, and global distribution initiatives.
